编号： 2022-004 仙乐健康科技股份有限公司 投资者关系活动记录表 证券代码：300791 证券简称：仙乐健康 证券代码：123113 证券简称：仙乐转债 仙乐健康科技股份有限公司 2022 年 5 月 13 日投资者关系活动记录表 | --- | --- | |-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | ■特定对 ...

仙乐健康科技股份有限公司 投资者关系活动记录表 证券代码：300791 证券简称：仙乐健康 证券代码：123113 证券简称：仙乐转债 仙乐健康科技股份有限公司 2022 年 5 月 27 日投资者关系活动记录表 编号： 2022-005 | --- | --- | |---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

仙乐健康科技股份有限公司 投资者关系活动记录表 证券代码：300791 证券简称：仙乐健康 证券代码：123113 证券简称：仙乐转债 仙乐健康科技股份有限公司 2022 年 9 月 22 日投资者关系活动记录表 编号： 2022-007 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------------------|------------------------------------------------------------------| | 投资者关系 \n活动类别 | □特定对象调研 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n□现场参观 \n■其他（ 2022 | □分析师会议 \n年广东辖区上市公司投资者集体接待日） | | 参与单位名称 及人员姓名 | 投资者网上提问 | | | 时间 | 2022 年 9 月 22 日 15:50-16:50 | | | 方式 | 公司 ...

仙乐健康科技股份有限公司 投资者关系活动记录表 证券代码：300791 证券简称：仙乐健康 证券代码：123113 证券简称：仙乐转债 仙乐健康科技股份有限公司 2022 年 8 月 26 日投资者关系活动记录表 编号： 2022-006 | --- | --- | --- | |-----------------------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

仙乐健康科技股份有限公司 投资者关系活动记录表 证券代码：300791 证券简称：仙乐健康 仙乐健康科技股份有限公司 2022 年 10 月 26 日投资者关系活动记录表 编号： 2022-008 | --- | --- | --- | --- | |------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------------| | | | | | | | ■特定对象调研 □分析师会议 | | | | 投资者关系 | □媒体采访 | | | | 活 ...

Financial Performance - The company's revenue for Q3 2022 was ¥676,865,104.35, representing a year-over-year increase of 16.11%[5] - Net profit attributable to shareholders for the same period was ¥66,253,052.91, up 21.33% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥65,405,277.67, reflecting a 25.80% increase year-over-year[5] - The company's basic earnings per share for Q3 2022 was ¥0.37, an increase of 23.33% compared to the same period last year[5] - Net profit for the third quarter of 2022 was CNY 176,169,128.33, a decrease of 12.06% compared to CNY 200,383,925.05 in the same period last year[74] - Total revenue from sales of goods and services reached CNY 2,028,245,946.14, up from CNY 1,845,335,283.73 year-on-year, representing an increase of 9.88%[78] - Operating profit for the quarter was CNY 210,154,581.61, down from CNY 237,056,672.55, reflecting a decline of 11.34%[74] - Total comprehensive income for the quarter was CNY 175,033,665.64, down from CNY 187,053,709.00, a decrease of 6.83%[76] - Basic earnings per share were CNY 0.98, down from CNY 1.11 in the same quarter last year, reflecting a decline of 11.71%[76] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,065,042,753.66, marking a 6.41% increase from the end of the previous year[5] - The company's total liabilities increased to RMB 1,398 million from RMB 1,275 million, representing a rise of approximately 9.6% year-to-date[44] - The company's equity attributable to shareholders reached RMB 2,667 million, up from RMB 2,545 million, indicating an increase of about 4.8%[57] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥344,494,899.47, up 15.59% compared to the previous year[5] - The company reported a net cash inflow from operating activities of CNY 344,494,899.47, compared to CNY 298,028,406.20 in the previous year, an increase of 15.56%[82] - Investment activities resulted in a net cash outflow of CNY 68,894,199.27, an improvement from a net outflow of CNY 414,821,096.01 in the previous year[82] - Net cash flow from financing activities was -$71.81 million, compared to $948.33 million in the previous period[84] - Total cash and cash equivalents at the end of the period amounted to $923.44 million, up from $1.04 billion in the previous period[84] - The initial cash and cash equivalents balance was $708.73 million, leading to a significant increase by the end of the period[84] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,368, with Guangdong Guanghui Investment Co., Ltd. holding 43.16% of shares[14] - The top 10 shareholders include several individuals with significant stakes, such as Chen Qiong with 7.48% and Lin Peiqing with 7.19%[14] - The total number of restricted shares at the beginning of the period was 16,588,800, which were all released during the period, resulting in zero restricted shares at the end[19] Investments and Acquisitions - The company completed the acquisition of 80% equity in BestFormulationsInc. on July 6, 2022, which is part of its fundraising project for issuing A-shares[20] - The company has passed the U.S. antitrust review for the acquisition of BestFormulationsInc.[23] - The company is uncertain if the acquisition will be approved by the shareholders' meeting, as it requires a two-thirds majority vote[23] - The company raised up to RMB 1,350 million through a targeted issuance of A-shares, with the net proceeds allocated for acquiring 80% of BestFormulations Inc. and supplementing working capital[24] Government Support and Subsidies - The company received government subsidies amounting to ¥3,277,129.80 during the reporting period, contributing to its financial performance[8] Research and Development - Research and development expenses amounted to CNY 60,745,994.30, slightly up from CNY 59,244,496.97, indicating a focus on innovation[74] Cost Management - Total operating costs for the third quarter of 2022 were RMB 1,602 million, compared to RMB 1,534 million in the previous year, marking an increase of about 4.4%[67] - Sales expenses decreased to CNY 86,670,799.62 from CNY 105,774,897.86, a reduction of 18.05%, indicating cost control measures[74] Miscellaneous - The company has obtained necessary approvals for overseas investment, including the issuance of the Overseas Investment Certificate by the Guangdong Provincial Department of Commerce[23] - The company has completed the foreign investment project filing procedures with the Guangdong Provincial Development and Reform Commission[23] - The company does not know if there are any related party relationships among the top 10 unrestricted shareholders[17] - The company has not disclosed any related party transactions in the acquisition of BestFormulationsInc.[20] - The company’s board of directors issued the report on October 26, 2022[86] - The company did not undergo an audit for the third quarter report[85]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥1.11 billion, a decrease of 4.60% compared to ¥1.17 billion in the same period last year[22]. - The net profit attributable to shareholders decreased by 24.60% to approximately ¥109.92 million from ¥145.78 million year-on-year[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥96.31 million, down 27.72% from ¥133.24 million in the previous year[22]. - Basic earnings per share decreased by 24.69% to ¥0.61 from ¥0.81 in the previous year[22]. - The gross profit margin for the main business was 31.85%, down 2.83% year-on-year[76]. - The second quarter of 2022 showed improvement with a revenue increase of 4.97% and a net profit increase of 7.76% compared to the same period last year[38]. - The company reported a significant increase in revenue, achieving a year-on-year growth of 20% in the first half of 2022[149]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2022, representing a year-over-year growth of 25%[151]. Cash Flow and Assets - The net cash flow from operating activities increased by 35.29% to approximately ¥214.22 million, compared to ¥158.34 million in the same period last year[22]. - Total assets at the end of the reporting period were approximately ¥3.97 billion, an increase of 3.81% from ¥3.82 billion at the end of the previous year[22]. - The company's total assets included cash and cash equivalents of ¥745.94 million, accounting for 18.81% of total assets[79]. - The cash and cash equivalents decreased by 96.74% to ¥31.54 million, primarily due to the absence of funds raised from convertible bonds compared to the previous year[74]. - The company reported a cumulative investment income of CNY 15.93 million from financial products[88]. Research and Development - R&D investment for the first half of 2022 was CNY 39.621 million, a decrease of 1.91% year-on-year due to delays caused by the pandemic[40]. - The company emphasizes the introduction of high-end R&D talent and investment in R&D as a foundation for enhancing its product development capabilities[58]. - The company is investing in R&D, with a budget increase of 30% for new technology development[149]. - The company is investing heavily in R&D, with a budget allocation of 150 million for new technology development in 2022[151]. Market and Sales - Domestic sales revenue was CNY 673 million, a decline of 8.44%, while overseas sales revenue reached CNY 435 million, an increase of 1.89%[38]. - The company is focusing on organizational restructuring to enhance market insight and product innovation, aiming to maintain its competitive advantage[107]. - The company is accelerating its international strategy, aiming to become a leading player in the global nutrition and health food CDMO sector, with a focus on the U.S. market[44]. - Market expansion plans include entering three new international markets by Q4 2022, aiming for a 10% market share in each[151]. Acquisitions and Investments - The company successfully reached an agreement to acquire 80% of Best Formulation Inc., a leading North American contract manufacturer, enhancing its production capacity and industry resources[45]. - The company approved the acquisition of 80% equity in Best Formulations Inc. during the board meeting on July 6, 2022[176]. - The company is considering strategic acquisitions to enhance its product portfolio, targeting a deal valued at approximately $100 million[149]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million allocated for potential mergers and acquisitions[151]. Risk Management - The company faces risks including COVID-19 pandemic risks, product quality management risks, and intensified market competition risks[6]. - The company has established an emergency response team to mitigate risks associated with the ongoing COVID-19 pandemic[103]. - The company is exposed to foreign exchange risks due to significant export activities, particularly in the Americas and Europe[108]. - The company employs strategies such as locking exchange rates with banks to manage foreign exchange risk effectively[108]. Corporate Governance and Shareholder Matters - The company did not distribute cash dividends or bonus shares for the first half of 2022[119]. - The participation rate of investors in the 2022 first extraordinary general meeting was 72.75%[117]. - The company plans to implement a stock incentive plan as part of its employee motivation strategy[120]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its initial public offering[147]. Social Responsibility and Sustainability - The company emphasizes sustainable development and environmental protection, implementing green office practices and reducing unnecessary travel[136]. - The company donated a total of 550,000 RMB in cash and materials to support pandemic prevention efforts in Hong Kong, including 200,000 RMB in cash and 20,000 masks[143]. - The company has invested in its own wastewater treatment facilities at each plant to ensure compliance with discharge standards[136]. - The company achieved a 100% signing rate of the social responsibility commitment letter among direct material suppliers during the reporting period[137].

Financial Performance - The company reported a net profit of 158.59 million yuan, accounting for 6.23% of the total equity attributable to shareholders at the end of the reporting period[14]. - The company's operating revenue for 2021 was CNY 2,368,947,616.87, representing a 14.62% increase compared to CNY 2,066,817,765.70 in 2020[34]. - The net profit attributable to shareholders for 2021 was CNY 231,834,489.00, a decrease of 9.92% from CNY 257,366,015.36 in the previous year[34]. - The net profit after deducting non-recurring gains and losses was CNY 209,799,088.33, down 5.61% from CNY 222,278,606.64 in 2020[34]. - The company's total assets increased by 44.17% to CNY 3,820,110,170.19 at the end of 2021, compared to CNY 2,649,636,693.93 at the end of 2020[34]. - The basic earnings per share for 2021 was CNY 1.29, a decrease of 9.79% from CNY 1.43 in 2020[34]. - The weighted average return on net assets was 9.77% in 2021, down from 12.48% in 2020[34]. - The net cash flow from operating activities for 2021 was CNY 341,377,365.21, an increase of 6.82% from CNY 319,573,018.84 in 2020[34]. - The total equity attributable to shareholders increased by 16.59% to CNY 2,544,779,706.22 at the end of 2021, compared to CNY 2,182,687,275.64 at the end of 2020[34]. - The company achieved operating revenue of 2.369 billion yuan in 2021, representing a year-on-year growth of 14.62%[60]. Dividend Distribution - The company plans to distribute a cash dividend of 4 yuan per 10 shares to all shareholders, based on a total of 180,169,870 shares[14]. Quality Management and Compliance - The company has a quality management team with over 20 years of experience in the nutrition and health food sector, ensuring product safety and compliance with evolving standards[8]. - The company emphasizes the importance of quality management across all levels of its operations to prevent potential product safety risks[8]. - The company is committed to continuous improvement in its internal control standards to align with new policies and regulations in the nutrition and health food industry[11]. - The company has a recognized inspection center equipped with advanced testing equipment to enhance its quality control capabilities[8]. - The company is actively involved in the formulation and revision of industry regulations to mitigate operational risks associated with regulatory changes[11]. Product Development and Innovation - The company is focusing on product innovation and market-driven management to maintain its competitive edge amid increasing industry competition[12]. - The company aims to become an innovation leader in the nutrition and health sector, with a vision to be the first choice for customers[60]. - The company has over 4,000 mature nutrition and health food product formulas, addressing diverse health needs across different age groups[59]. - The company has a diverse product development strategy, including self-developed products and customized products based on client needs[72]. - The company has introduced multiple new products, including various vitamin and mineral supplements, enhancing its product portfolio[102]. Market Presence and Sales - Domestic sales revenue reached 1.458 billion yuan, growing by 14.06% year-on-year, while overseas sales revenue was 911 million yuan, up 15.60% year-on-year[60]. - The company operates in the nutrition and health food sector, focusing on contract development and manufacturing (CDMO) for B-end clients[53]. - The company has established production bases and marketing centers in China, Germany, and the United States, enhancing its global market presence[53]. - The company sold 663.51 million units of its products, marking a year-on-year increase of 16.88%[110]. - The soft candy segment experienced significant growth, with revenue increasing by 44.22% to approximately CNY 471.94 million[107]. Research and Development - The company invested CNY 83.19 million in R&D during the first half of 2021, representing a year-on-year increase of 28.56%[61]. - The company submitted 35 invention patent applications during the reporting period, reflecting its commitment to continuous innovation[61]. - The number of R&D personnel increased by 18.22% to 318, with R&D personnel accounting for 12.95% of the total workforce[126]. - The company has established a comprehensive R&D center recognized as the "Guangdong Province International Engineering Technology Research Center for Nutritional Health Food" and "Guangdong Province Enterprise Technology Center"[82]. Operational Efficiency - The company has established a digital factory project to enhance operational efficiency through lean operations and supply chain optimization[66]. - The company aims to establish an excellent supply chain to reduce costs and increase efficiency, integrating resources across the entire process from design to service[172]. - The company has implemented measures to manage foreign exchange risks due to significant export activities, particularly in the Americas and Europe[13]. Future Outlook - Future outlook indicates continued growth in revenue driven by new product development and market expansion strategies[103]. - The company plans to enhance its research and development efforts to introduce more health-focused products in response to market demand[103]. - The company aims to maintain a strong position in the health supplement market by leveraging innovative technologies in product formulation[103]. - The company anticipates a shift in health consumption demographics towards younger groups, with an increase in preventive health needs and diversified product offerings[161]. Governance and Compliance - The company has established an independent, complete, and standardized financial accounting system and management system, allowing for independent financial decision-making[200]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[189]. - The company has a performance evaluation system linking employee income to work performance and company performance[192]. - The company actively respects and protects the legitimate rights and interests of stakeholders, promoting balanced interests among shareholders, employees, and society[191].

Financial Performance - The company's revenue for Q1 2022 was ¥421,248,609.14, representing a decrease of 17.01% compared to ¥507,560,431.75 in the same period last year[3] - Net profit attributable to shareholders was ¥14,638,612.62, down 74.48% from ¥57,360,400.88 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥4,309,880.47, a decline of 91.80% compared to ¥52,543,436.24 in the previous year[3] - Basic earnings per share were ¥0.32, reflecting a decrease of 75.00% from the previous year[4] - Total operating revenue for the current period is ¥421,248,609.14, a decrease of 17.0% from ¥507,560,431.75 in the previous period[20] - Net profit for the current period is ¥14,638,612.62, a decline of 74.5% compared to ¥57,360,400.88 in the previous period[22] - Operating profit decreased significantly to ¥17,746,209.01, down 75.2% from ¥71,514,280.72 in the previous period[22] - Total comprehensive income for the current period is ¥14,138,814.21, down 73.6% from ¥53,416,011.26 in the previous period[24] - Basic earnings per share decreased to ¥0.08 from ¥0.32 in the previous period, reflecting a 75.0% decline[24] Cash Flow - The net cash flow from operating activities increased significantly to ¥19,502,319.27, marking a 613.94% increase[4] - Cash flow from operating activities generated ¥139,235,270.31, a substantial increase from ¥19,502,319.27 in the previous period[27] - Net cash flow from financing activities was -1,426,287.02, compared to -188,744.43 in the previous period[28] - Cash and cash equivalents at the end of the period totaled 654,971,448.23, down from 708,732,992.29 at the beginning of the period[28] - The net increase in cash and cash equivalents was -53,761,544.06, compared to -29,760,225.19 in the previous period[28] - Cash inflow from financing activities amounted to 1,747.50[28] - Cash outflow for dividend distribution, profit, or interest payments was 142,541.93[28] - The impact of exchange rate changes on cash and cash equivalents was -544,121.66[28] - The company reported a cash flow from financing activities net amount of -1,426,287.02[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,820,110,170.19, showing a slight increase of 0.80%[4] - The total assets of the company increased to RMB 3,850,720,519.92 from RMB 3,820,110,170.19, reflecting a growth of approximately 0.8%[19] - Current assets decreased to RMB 1,860,827,021.99 from RMB 1,914,522,146.55, a decline of about 2.8%[15] - Cash and cash equivalents at the end of the period were RMB 660,301,918.94, down from RMB 715,544,087.29, representing a decrease of approximately 7.7%[13] - Accounts receivable decreased significantly to RMB 228,352,215.15 from RMB 341,758,634.13, a reduction of about 33.3%[13] - Inventory increased to RMB 299,895,377.28 from RMB 239,613,375.43, marking an increase of approximately 25.2%[13] - Total liabilities rose to RMB 1,287,387,493.27 from RMB 1,275,330,463.97, an increase of about 0.9%[17] - The company's equity attributable to shareholders increased to RMB 2,563,333,026.65 from RMB 2,544,779,706.22, reflecting a growth of approximately 0.7%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,857[8] - The largest shareholder, Guangdong Guanghui Investment Co., Ltd., held 43.16% of the shares, totaling 77,760,000 shares[8] Expenses - Total operating costs decreased to ¥418,839,974.40, down 5.7% from ¥444,345,727.83 in the previous period[20] - Research and development expenses increased to ¥18,723,894.19, up 6.7% from ¥17,541,154.80 in the previous period[20] - Financial expenses rose to ¥10,524,804.69, an increase of 72.5% from ¥6,116,844.80 in the previous period[22] - Other income increased to ¥7,208,240.83, up 72.5% from ¥4,175,224.20 in the previous period[22] Other Information - The company reported a significant increase in prepaid expenses, which rose by 255.02% to ¥43,915,383.92[7] - The company reported a decrease in employee compensation payable from RMB 37,802,330.45 to RMB 17,368,648.10, a decline of about 54.0%[16] - The company’s long-term investments increased to RMB 390,567,465.84 from RMB 337,791,232.93, an increase of approximately 15.6%[15] - The company’s total non-current assets rose to RMB 1,989,893,497.93 from RMB 1,905,588,023.64, an increase of about 4.4%[15] - The first quarter report was not audited[29]

Financial Performance - The company's revenue for 2021 was CNY 2,368,947,616.87, representing a 14.62% increase compared to CNY 2,066,817,765.70 in 2020[43]. - The net profit attributable to shareholders for 2021 was CNY 231,834,489.00, a decrease of 9.92% from CNY 257,366,015.36 in the previous year[43]. - The net cash flow from operating activities for 2021 was CNY 341,377,365.21, reflecting a 6.82% increase from CNY 319,573,018.84 in 2020[43]. - The total assets at the end of 2021 amounted to CNY 3,820,110,170.19, which is a 44.17% increase from CNY 2,649,636,693.93 at the end of 2020[43]. - The basic earnings per share for 2021 was CNY 1.29, down 9.79% from CNY 1.43 in 2020[43]. - The diluted earnings per share for 2021 was CNY 1.22, a decrease of 14.08% compared to CNY 1.42 in the previous year[43]. - The company's weighted average return on equity for 2021 was 9.77%, down from 12.48% in 2020[43]. - The company reported a net profit of CNY 57,360,400.89 in Q1 2021, with total revenue of CNY 507,560,431.75 for the same quarter[47]. - The total cost of goods sold for 2021 was CNY 1.59 billion, compared to CNY 1.39 billion in 2020, reflecting an increase in operational scale[84]. - The company reported a total of 22.035 million yuan in non-recurring gains and losses for the year, down from 35.087 million yuan in 2020[54]. Market and Product Development - The company plans to continue expanding its market presence and invest in new product development[41]. - The company is focusing on market demand insights and product innovation to maintain competitive advantages in a rapidly growing industry[13]. - The company has over 4,000 mature nutritional health product formulas to meet diverse health needs across different age groups[68]. - The company operates in the CDMO sector, focusing on B-end market services, and aims to be a leader in the nutritional health field[69]. - The company launched multiple new health food products in 2021, including 43 new items registered with health food certificates[112][115]. - The company is focusing on research and development of new products to enhance its competitive edge in the market[116]. - The company aims to enhance its innovation capabilities and establish a research plan for identifying innovation points, with a focus on product planning and cross-functional team collaboration[186]. - The company intends to enhance its product development capabilities and continuously iterate on key products and technologies, focusing on soft capsules, gummies, and beverages[189]. Operational Efficiency and Quality Management - The company has implemented advanced quality management electronic systems to optimize quality control processes[9]. - The company has established a digital factory project aimed at enhancing operational efficiency through smart manufacturing and supply chain optimization[75]. - The company has adopted a strategy of organizational restructuring to enhance market responsiveness and operational efficiency[13]. - The beverage workshop at the Ma'anshan production base has been integrated for unified intelligent management, with three new production lines added in Q3 2021, including two for bagged beverages with an annual capacity of 100 million bags[74]. - The company aims to establish an excellent supply chain to reduce costs and increase efficiency, integrating all processes from design to service[190]. Research and Development - The company has two R&D platforms and a doctoral workstation to facilitate rapid product development and market introduction[68]. - The company invested CNY 83.19 million in R&D during the first half of 2021, representing a year-on-year increase of 28.56%[70]. - The number of R&D personnel increased by 18.22% to 318, representing 12.95% of the total workforce[141]. - The company submitted 35 invention patent applications during the reporting period, benefiting from prior reserves and ongoing R&D efforts[70]. - As of December 31, 2021, the company and its subsidiaries owned 50 patents, including 21 invention patents, with 4 new invention patents added in 2021[102]. Global Presence and Market Strategy - The company has established production bases and marketing centers in China, Germany, and the United States, enhancing its global market presence[62]. - The company has marketing centers in the U.S. and Europe, and a production base in Germany, allowing for localized service and better integration into the global high-end product market[92]. - In the Americas, the company will enhance market share through local supply chains and deep cooperation with major retail clients[194]. - In Europe, the company aims to achieve regional leadership through product innovation and optimizing local supply chains[194]. - The company plans to expand its market presence in China by focusing on major customers and leveraging global insights for product innovation[194]. Risk Management and Compliance - The company is exposed to foreign exchange risks due to significant export activities, particularly in the Americas and Europe[14]. - The company is actively involved in the formulation and revision of industry laws and regulations to ensure compliance with the latest policies[12]. - The company acknowledges potential risks and has outlined measures to address them in its report[196]. Consumer Trends and Market Outlook - The nutritional health food industry is expected to maintain a strong growth trend over the next five years, driven by increased consumer health awareness due to the pandemic[59]. - The health awareness among consumers has significantly increased, leading to a notable rise in healthcare spending[178]. - The health consumption demographic is shifting towards younger consumers, increasing the demand for diverse health products[179]. - The company anticipates continued growth in the nutrition and health market driven by policy support and capital investment[181].